Sun Pharma Advanced Research Company reported positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the
treatment of Inflammation and Pain associated with Ocular Surgery. The trial met its prespecified primary and secondary objectives, demonstrating that SDN-037 is superior to its vehicle.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
